Association analysis of urotensin ii gene (uts2) and flanking regions with biochemical parameters related to insulin resistance

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Sáez, María E ^a   Smani, Tarik ^b   Ramírez Lorca, Reposo ^a   Díaz, Ignacio ^b   Serrano Ríos, Manuel ^c   Ruiz, Agustín ^a   Ordoñez, Antonio ^b  

^a Department of Structural Genomics ^*  (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DNA FLANKING REGION; FEMALE; GENE; GENE FUNCTION; GENE LOCATION; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HAPLOTYPE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PER3 GENE; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UROTENSIN II GENE;

CHROMOSOME MAPPING; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; INSULIN RESISTANCE; MALE; PERIOD CIRCADIAN PROTEINS; PHENOTYPE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, G-PROTEIN-COUPLED; SPAIN; UROTENSINS;

EID: 79955783695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019327     Document Type: Article

References (57)

1. Davenport AP, Maguire JJ, (2000) Urotensin II: fish neuropeptide catches orphan receptor. Trends Pharmacol Sci 21: 80-82.
2. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, et al. (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286.
3. Ong KL, Lam KS, Cheung BM, (2005) Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther 19: 65-75.
4. Vaudry H, Do Rego JC, Le Mevel JC, Chatenet D, Tostivint H, et al. (2010) Urotensin II, from fish to human. Ann N Y Acad Sci 1200: 53-66.
5. Ross B, McKendy K, Giaid A, (2010) Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol 298: R1156-1172.
6. Silvestre RA, Egido EM, Hernandez R, Leprince J, Chatenet D, et al. (2004) Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 151: 803-809.
7. Silvestre RA, Rodriguez-Gallardo J, Egido EM, Marco J, (2001) Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas. Horm Metab Res 33: 379-381.
8. Ong KL, Wong LY, Cheung BM, (2008) The role of urotensin II in the metabolic syndrome. Peptides 29: 859-867.
9. Sun HX, Du WN, Zuo J, Wu GD, Shi GB, et al. (2002) [The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of northern China]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24: 223-227.
10. Suzuki S, Wenyi Z, Hirai M, Hinokio Y, Suzuki C, et al. (2004) Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 25: 1803-1808.
11. Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, et al. (2003) Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia 46: 972-976.
12. Tan YJ, Fan ZT, Yang HX, (2006) [Role of urotensin II gene in the genetic susceptibility to gestational diabetes mellitus in northern Chinese women]. Zhonghua Fu Chan Ke Za Zhi 41: 732-735.
13. Zhu F, Ji L, Luo B, (2002) [The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population]. Zhonghua Yi Xue Za Zhi 82: 1473-1475.
14. Ong KL, Wong LY, Man YB, Leung RY, Song YQ, et al. (2006) Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 27: 1659-1667.
15. Suguro T, Watanabe T, Kodate S, Xu G, Hirano T, et al. (2008) Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin Sci (Lond) 115: 327-334.
16. Jiang Z, Michal JJ, Tobey DJ, Wang Z, Macneil MD, et al. (2008) Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2 diabetes mellitus. Int J Biol Sci 4: 96-102.
17. Yi L, Gu YH, Wang XL, An LZ, Xie XD, et al. (2006) Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. J Int Med Res 34: 272-283.
18. Nishihama K, Yamada Y, Matsuo H, Segawa T, Watanabe S, et al. (2007) Association of gene polymorphisms with myocardial infarction in individuals with or without conventional coronary risk factors. Int J Mol Med 19: 129-141.
19. Oguri M, Kato K, Yokoi K, Itoh T, Yoshida T, et al. (2009) Association of genetic variants with myocardial infarction in Japanese individuals with metabolic syndrome. Atherosclerosis 206: 486-493.
20. Gayan J, Galan JJ, Gonzalez-Perez A, Saez ME, Martinez-Larrad MT, et al. (2010) Genetic Structure of the Spanish Population. BMC Genomics 11: 326.
21. Gangwisch JE, (2009) Epidemiological evidence for the links between sleep, circadian rhythms and metabolism. Obes Rev 10 (Suppl 2): 37-45.
22. Ando H, Takamura T, Matsuzawa-Nagata N, Shima KR, Eto T, et al. (2009) Clock gene expression in peripheral leucocytes of patients with type 2 diabetes. Diabetologia 52: 329-335.
23. Ando H, Ushijima K, Kumazaki M, Takamura T, Yokota N, et al. (2010) Influence of age on clock gene expression in peripheral blood cells of healthy women. J Gerontol A Biol Sci Med Sci 65: 9-13.
24. Chu LW, Zhu Y, Yu K, Zheng T, Chokkalingam AP, et al. (2008) Correlation between circadian gene variants and serum levels of sex steroids and insulin-like growth factor-I. Cancer Epidemiol Biomarkers Prev 17: 3268-3273.
25. Guess J, Burch JB, Ogoussan K, Armstead CA, Zhang H, et al. (2009) Circadian disruption, Per3, and human cytokine secretion. Integr Cancer Ther 8: 329-336.
26. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, et al. (2007) A genome-wide association study of global gene expression. Nat Genet 39: 1202-1207.
27. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, et al. (2007) Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448: 470-473.
28. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, et al. (2003) Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 104: 1-5.
29. Liu F, Zhu YC, (2010) [Urotensin II inhibits glucokinase expression and glucose-induced insulin secretion.]. Sheng Li Xue Bao 62: 129-136.
30. Silvestre RA, Egido EM, Hernandez R, Marco J, (2009) Characterization of the insulinostatic effect of urotensin II: a study in the perfused rat pancreas. Regul Pept 153: 37-42.
31. Gruson D, Ginion A, Decroly N, Lause P, Vanoverschelde JL, et al. (2010) Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. Peptides 31: 1326-1333.
32. Sheridan MA, Plisetskaya EM, Bern HA, Gorbman A, (1987) Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 66: 405-414.
33. Tooke JE, Hannemann MM, (2000) Adverse endothelial function and the insulin resistance syndrome. J Intern Med 247: 425-431.
34. Gruson D, Rousseau MF, Ketelslegers JM, Hermans MP, (2010) Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J Clin Hypertens (Greenwich) 12: 653-660.
35. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, et al. (2003) Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93: 246-253.
36. Papadopoulos P, Bousette N, Giaid A, (2008) Urotensin-II and cardiovascular remodeling. Peptides 29: 764-769.
37. Ainla T, Baburin A, Teesalu R, Rahu M, (2005) The association between hyperglycaemia on admission and 180-day mortality in acute myocardial infarction patients with and without diabetes. Diabet Med 22: 1321-1325.
38. Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Del Pinto M, et al. (2010) New-onset hyperglycemia and acute coronary syndrome: a systematic overview and meta-analysis. Curr Diabetes Rev 6: 102-110.
39. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, et al. (2005) Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 111: 3078-3086.
40. Milvidaite I, Slapikas R, Statkeviciene A, Babarskiene MR, Luksiene D, et al. (2007) [Admission hyperglycemia and abnormal glucose tolerance at discharge in patients with acute myocardial infarction and no previous history of diabetes mellitus]. Medicina (Kaunas) 43: 935-941.
41. Petursson P, Herlitz J, Caidahl K, Gudbjornsdottir S, Karlsson T, et al. (2007) Admission glycaemia and outcome after acute coronary syndrome. Int J Cardiol 116: 315-320.
42. Schiele F, Descotes-Genon V, Seronde MF, Blonde MC, Legalery P, et al. (2006) Predictive value of admission hyperglycaemia on mortality in patients with acute myocardial infarction. Diabet Med 23: 1370-1376.
43. Stranders I, Diamant M, van Gelder RE, Spruijt HJ, Twisk JW, et al. (2004) Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med 164: 982-988.
44. Kolman L, Hu YC, Montgomery DG, Gordon K, Eagle KA, et al. (2009) Prognostic value of admission fasting glucose levels in patients with acute coronary syndrome. Am J Cardiol 104: 470-474.
45. Thalib L, Zubaid M, Rashed W, Suwaidi JA, Almahmeed W, et al. (2010) Impact of Diabetic Status on the Hyperglycaemia Induced Adverse Risk of Short Term Outcomes in Hospitalized Patients with Acute Coronary Syndromes in the Middle East: Findings from the Gulf Registry of Acute Coronary Events (Gulf RACE). Clin Med Res.
46. Clozel M, Hess P, Qiu C, Ding SS, Rey M, (2006) The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 316: 1115-1121.
47. Marco J, Egido EM, Hernandez R, Silvestre RA, (2008) Evidence for endogenous urotensin-II as an inhibitor of insulin secretion. Study in the perfused rat pancreas. Peptides 29: 852-858.
48. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, et al. (2006) Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 80: 246-256.
49. Sidharta PN, Rave K, Heinemann L, Chiossi E, Krahenbuhl S, et al. (2009) Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus. Br J Clin Pharmacol 68: 502-510.
50. Vogt L, Chiurchiu C, Chadha-Boreham H, Danaietash P, Dingemanse J, et al. (2010) Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. Hypertension 55: 1206-1209.
51. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gabriel R, Williams K, et al. (2001) Was the historic contribution of Spain to the Mexican gene pool partially responsible for the higher prevalence of type 2 diabetes in mexican-origin populations? The Spanish Insulin Resistance Study Group, the San Antonio Heart Study, and the Mexico City Diabetes Study. Diabetes Care 24: 2059-2064.
52. Martinez-Larrad MT, Fernandez-Perez C, Gonzalez-Sanchez JL, Lopez A, Fernandez-Alvarez J, et al. (2005) [Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia]. Med Clin (Barc) 125: 481-486.
53. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, et al. (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26: 3160-3167.
54. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
55. Li Y, Abecasis GR, (2006) Mach 1.0: Rapid haplotype reconstruction and missing genotype inference. Am J Hum Genet S79: 2290.
56. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
57. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.